Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Recurrence 2Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Azacitidine 38Cytarabine 22venetoclax 19fludarabine phosphate 18fludarabine 18Cyclophosphamide 18Peripheral Blood Stem Cell Transplantation 15Tacrolimus 14Filgrastim 13Decitabine 13Mycophenolic Acid 12Busulfan 12Whole-Body Irradiation 11Melphalan 11Methotrexate 10Cyclosporine 10Antilymphocyte Serum 8Stem Cell Transplantation 7Alemtuzumab 7decitabine and cedazuridine drug combination 6Granulocyte Colony-Stimulating Factor 6Clofarabine 6AP 1903 reagent 6Thiotepa 5Rituximab 5Idarubicin 5quizartinib 4Tretinoin 4Sirolimus 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Myelodysplastic Syndromes × mocetinostat × Clear all
NCT00324220 2015-07-01

A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia

Mirati Therapeutics Inc.

Phase 1/2 Completed
66 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡